

# Erika Graf

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5665009/publications.pdf>

Version: 2024-02-01

41  
papers

1,803  
citations

393982

19  
h-index

377514

34  
g-index

54  
all docs

54  
docs citations

54  
times ranked

2835  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing the effect of a regional integrated care model over ten years using quality indicators based on claims data – the basic statistical methodology of the INTEGRAL project. BMC Health Services Research, 2022, 22, 247.	0.9	4
2	Statistical advising: Professional development opportunities for the biostatistician. Statistics in Medicine, 2022, 41, 847-859.	0.8	2
3	Multimodal treatment efficacy differs in dependence of core symptom profiles in adult Attention-Deficit/Hyperactivity Disorder: An analysis of the randomized controlled COMPAS trial. Journal of Psychiatric Research, 2022, 151, 225-234.	1.5	3
4	Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL. Journal of Hepatology, 2022, 77, 695-701.	1.8	30
5	Primary dementia care based on the individual needs of the patient: study protocol of the cluster randomized controlled trial, DemStepCare. BMC Geriatrics, 2021, 21, 222.	1.1	12
6	Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. Lancet Respiratory Medicine, 2021, 9, 755-762.	5.2	129
7	Does helping mothers in multigenerational ADHD also help children in the long run? 2-year follow-up from baseline of the AIMAC randomized controlled multicentre trial. European Child and Adolescent Psychiatry, 2020, 29, 1425-1439.	2.8	3
8	Comparison of complex modeling strategies for prediction of a binary outcome based on a few, highly correlated predictors. Biometrical Journal, 2020, 62, 568-582.	0.6	0
9	Development and validation of a prognostic model for survival in patients treated with venoarterial extracorporeal membrane oxygenation: the PREDICT VA-ECMO score. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 350-359.	0.4	56
10	Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms. JAMA Network Open, 2019, 2, e194980.	2.8	36
11	Effect and safety of treatment with ACE-inhibitor Enalapril and $\beta$ -blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial. Orphanet Journal of Rare Diseases, 2019, 14, 105.	1.2	21
12	A multicentre randomized controlled trial on trans-generational attention deficit/hyperactivity disorder (ADHD) in mothers and children (AIMAC): an exploratory analysis of predictors and moderators of treatment outcome. Zeitschrift Für Kinder- Und Jugendpsychiatrie Und Psychotherapie, 2019, 47, 49-65.	0.4	3
13	Second-Generation Hydrogel Coils for the Endovascular Treatment of Intracranial Aneurysms. Stroke, 2018, 49, 667-674.	1.0	46
14	Does the efficacy of parent-child training depend on maternal symptom improvement? Results from a randomized controlled trial on children and mothers both affected by attention-deficit/hyperactivity disorder (ADHD). European Child and Adolescent Psychiatry, 2018, 27, 1011-1021.	2.8	5
15	1-Hz rTMS in the treatment of tinnitus: A sham-controlled, randomized multicenter trial. Brain Stimulation, 2017, 10, 1112-1120.	0.7	38
16	Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer, 2016, 16, 769.	1.1	62
17	GREAT – a randomized controlled trial comparing HydroSoft/HydroFrame and bare platinum coils for endovascular aneurysm treatment: procedural safety and core-lab-assessed angiographic results. Neuroradiology, 2016, 58, 777-786.	1.1	31
18	Discrete Global but No Focal Gray Matter Volume Reductions in Unmedicated Adult Patients With Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry, 2016, 80, 905-915.	0.7	33

#	ARTICLE	IF	CITATIONS
19	Quality of Life of Adult Patients With Attention-Deficit/Hyperactivity Disorder Taking Methylphenidateâ€”Reply. <i>JAMA Psychiatry</i> , 2016, 73, 534.	6.0	1
20	Does intensive multimodal treatment for maternal <scp>ADHD</scp> improve the efficacy of parent training for children with <scp>ADHD</scp>? A randomized controlled multicenter trial. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2015, 56, 1298-1313.	3.1	42
21	Normal Neurochemistry in the Prefrontal and Cerebellar Brain of Adults with Attention-Deficit Hyperactivity Disorder. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 242.	1.0	17
22	Child impact on family functioning: a multivariate analysis in multiplex families with children and mothers both affected by attention-deficit/hyperactivity disorder (ADHD). <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2015, 7, 211-223.	1.7	15
23	Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder. <i>JAMA Psychiatry</i> , 2015, 72, 1199.	6.0	154
24	A randomized controlled multicenter trial on the multimodal treatment of adult attention-deficit hyperactivity disorder: enrollment and characteristics of the study sample. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2014, 6, 35-47.	1.7	32
25	A randomized controlled multicentre trial on the treatment for ADHD in mothers and children: enrolment and basic characteristics of the study sample. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2013, 5, 29-40.	1.7	13
26	German Validation of the Conners Adult ADHD Rating Scaleâ€”Self-Report. <i>Journal of Attention Disorders</i> , 2013, 17, 690-698.	1.5	46
27	Measures of prediction error for survival data with longitudinal covariates. <i>Biometrical Journal</i> , 2011, 53, 275-293.	0.6	16
28	Correction of confounding bias in nonâ€”randomized studies by appropriate weighting. <i>Biometrical Journal</i> , 2011, 53, 369-387.	0.6	16
29	BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. <i>BMC Cancer</i> , 2010, 10, 30.	1.1	77
30	Estimators and confidence intervals for the marginal odds ratio using logistic regression and propensity score stratification. <i>Statistics in Medicine</i> , 2010, 29, 760-769.	0.8	35
31	Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: Results of a randomised trial (GABG-IV) Tj ETQq1 1 0.734314 rsgBT /Ove		
32	Does the treatment of maternal attention deficit and hyperactivity disorder (ADHD) enhance the efficacy of a behavioural parent training for the treatment of their childrenâ€™s ADHD? Study protocol of a randomized controlled multicentre trial. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2009, 1, 33-45.	1.7	14
33	Design of a placebo-controlled, randomized study of the efficacy of repetitive transcranial magnetic stimulation for the treatment of chronic tinnitus. <i>BMC Psychiatry</i> , 2008, 8, 23.	1.1	36
34	Comments on â€”The performance of different propensity score methods for estimating marginal odds ratiosâ€™ by Peter C. Austin, <i>Statistics in Medicine</i> 2007; <b>26</b>(16):3078â€”3094. <i>Statistics in Medicine</i> , 2008, 27, 3915-3917.	0.8	8
35	A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer â€” GABG-IV B-93. <i>European Journal of Cancer</i> , 2007, 43, 2351-2358.	1.3	23
36	Stratification for the propensity score compared with linear regression techniques to assess the effect of treatment or exposure. <i>Statistics in Medicine</i> , 2007, 26, 5529-5544.	0.8	69

#	ARTICLE	IF	CITATIONS
37	CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: A randomised trial (GABG trial IV-A-93). <i>European Journal of Cancer</i> , 2006, 42, 1780-1788.	1.3	46
38	Assessment and comparison of prognostic classification schemes for survival data. , 1999, 18, 2529-2545.		584
39	Assessment and comparison of prognostic classification schemes for survival data. , 1999, 18, 2529.		1
40	The Propensity Score in the Analysis of Therapeutic Studies. <i>Biometrical Journal</i> , 1997, 39, 297-307.	0.6	10
41	An Investigation on Measures of Explained Variation in Survival Analysis. <i>Journal of the Royal Statistical Society: Series D (the Statistician)</i> , 1995, 44, 497.	0.2	17